New Developments on the Treatment of Liver Fibrosis

100Citations
Citations of this article
111Readers
Mendeley users who have this article in their library.

Abstract

Liver fibrosis results from many chronic injuries and often progresses to cirrhosis, liver failure, portal hypertension, and hepatocellular carcinoma. Liver transplantation is the only treatment available for patients with advanced stages of liver fibrosis. Therefore, new strategies for anti-fibrotic therapy are required. Various kinds of hepatocyte damage result in inflammation, which leads to the activation of hepatic stellate cells (HSCs), which are the major source of myofibroblasts in the liver. Myofibroblasts proliferate in response to various kinds of cytokines, chemokines, and growth factors and produce extracellular matrix proteins, which forms the fibrous scar. Myofibroblasts undergo apoptosis and inactivation when the underlying causative etiologies are cleared. Here we describe our current knowledge of targeting the steps in HSC activation as therapeutic target for liver fibrosis.

Cite

CITATION STYLE

APA

Koyama, Y., Xu, J., Liu, X., & Brenner, D. A. (2016). New Developments on the Treatment of Liver Fibrosis. Digestive Diseases, 34(5), 589–596. https://doi.org/10.1159/000445269

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free